BlueCrest Capital Management’s Medtronic MDT Stock Holding History

BlueCrest Capital Management’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,450	Closed	-$943K	–	255
2023 Q4	$943K	Sell	11,450 -6,773	-37%	-$516K	0.04%	174
2023 Q3	$1.43M	Buy	+18,223	New	+$1.53M	0.06%	159
2019 Q4	–	Sell	-2,206	Closed	-$240K	–	500
2019 Q3	$240K	Buy	+2,206	New	+$230K	0.02%	441
2019 Q2	–	Sell	-2,999	Closed	-$273K	–	799
2019 Q1	$273K	Sell	2,999 -8,452	-74%	-$756K	0.01%	759
2018 Q4	$1.04M	Buy	11,451 +1,987	+21%	+$186K	0.05%	205
2018 Q3	$931K	Sell	9,464 -8,087	-46%	-$748K	0.02%	471
2018 Q2	$1.5M	Buy	17,551 +14,642	+503%	+$1.22M	0.04%	407
2018 Q1	$233K	Buy	+2,909	New	+$240K	0.01%	1206
2017 Q4	–	Sell	-128,623	Closed	-$10M	–	991
2017 Q3	$10M	Buy	128,623 +107,288	+503%	+$8.91M	0.41%	60
2017 Q2	$1.89M	Buy	+21,335	New	+$1.8M	0.07%	349
2014 Q4	–	Sell	-4,035	Closed	-$250K	–	632
2014 Q3	$250K	Buy	+4,035	New	+$257K	0.01%	464

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlueCrest Capital Management's MDT Position: Q1 2024 in Review

BlueCrest Capital Management sold out of Medtronic (MDT) in Q1 2024, closing a stake of 11,450 shares — an estimated $943K sold.

BlueCrest Capital Management first reported a position in MDT in Q3 2014 and held it in 11 quarters. The position peaked at $10M in Q3 2017. 2,075 funds tracked by Wall St. Rank hold MDT as of Q1 2024.

BlueCrest Capital Management reported no remaining Medtronic position as of Q1 2024 after selling out during the quarter.
BlueCrest Capital Management sold 11,450 Medtronic shares in Q1 2024, an estimated $943K.
BlueCrest Capital Management first reported a position in Medtronic in Q3 2014 and held it in 11 quarters.
BlueCrest Capital Management's Medtronic position peaked at $10M in Q3 2017.
2,075 funds tracked by Wall St. Rank held Medtronic as of Q1 2024.

Based on BlueCrest Capital Management's 13F filing for Q1 2024, filed 15 May 2024.